Anlon Healthcare Q2 FY27 Earnings Call — Analysis (NSE: AHCL)

Anlon Healthcare doubled Q2FY27 revenue to ₹105.61 Cr with EBITDA margins recovering 610 bps QoQ to 23.9%, while maintaining aggressive FY27 revenue guidance of ₹380–₹400 Cr and FY28 target of ₹650–₹700 Cr driven by massive capacity additions.

6 Nov 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

Q2FY27 Revenue from Operations ₹105.61 Cr ( +102.32% YoY ) , H1FY27 +125.93% . New guidance — FY27 consolidated revenue fy27 ₹380 Cr to ₹400 Cr . New story: Downstream Vertical Integration & Diversificati… .

Results

Revenue ₹105.61 Cr +102.3% YoY; EBITDA margin 23.9% (+610 bps QoQ); PAT ₹17.18 Cr +84.4% YoY.

Financial highlights

Guidance

Management guided FY27 revenue of ₹380–₹400 Cr with 25–27% full-year EBITDA margin, scaling to ₹650–₹700 Cr revenue in FY28 post Rajkot capacity commissioning.

What management committed to

• We are expecting between INR380 crores to INR400 crores in FY27. — INR380 crores to INR400 crores, FY27
• We are expecting between INR650 crores to INR700 crores in FY28. — INR650 crores to INR700 crores, FY28
• We are hoping that we'll at least reach up to 25%, 26% at least in the total financial full year results by FY27 [EBITDA margin]. — 25%, 26%, FY27
• Our greenfield expansion at Rajkot will add roughly 1,200 metric tonne per annum through 8 new clean lines commissioning in Q1 FY28. — 1,200 metric tonne per annum, Q1FY28
• Apiqo expansion [500-600 MTPA] is expected to be complete by Q1 of FY28. — 500 to 600 MTPA, Q1FY28
• This is consistent with the commitment we made to deliver positive operating cash flow by end of FY27. — positive operating cash flow, FY27
• By Q4 [FY27], we'll start to get the revenue from Anlon Medicos. — Q4FY27
• By end of last month of Q3 or maybe first month of Q4, we can be able to supply the first commercial segment [for CDMO Molecule 1]. — Q4FY27
• Right now we are not having any plan to file the DMF directly for the U.S. of the Ketoprofen [on hold pending FDA audit trigger]. — on hold

Key themes

Multifold capacity expansion and downstream vertical integration

How the narrative shifted

• Downstream Vertical Integration & Diversification: Management is repositioning Anlon from an API/intermediate manufacturer into an integrated healthcare platform spanning CDMO, finished formulations, biologics, and orthopaedic surgical devices.
• Capacity Expansion and Scale Ramp-up: The massive 1,200 MTPA Rajkot greenfield project and subsidiary brownfield additions will drive the jump from ₹400 Cr revenue in FY27 to ₹700 Cr in FY28.
• Pricing Power and Margin Normalisation: Sequential margin recovery to 23.9% validates the pass-through of geopolitical input cost spikes to customers, setting the path toward steady-state 25-27% EBITDA margins.
• Global Sourcing Shift (China Plus One): Anlon positions itself as replacing Chinese suppliers in regulated markets (Japan, Europe, LATAM) with a 10%+ cost advantage and backward-integrated chemistry files.
• Working Capital and Cash Flow Turnaround: Tightened customer credit cycles and receivable collections are projected to convert FY26's deep operating cash burn into positive operating cash flows by FY27 end.

Operational commentary

• Installed group manufacturing capacity currently stands at 1,900–2,000 MTPA across parent and 5 entities; utilization is 85–86% at Anlon standalone and 65–67% consolidated.
• Greenfield Rajkot expansion of 1,200 MTPA (8 clean lines) for ₹130 Cr capex is under construction; civil ground floor progressing, commissioning expected in Q1FY28 with revenue commercialisation starting Q2FY28.
• Share swap to complete 100% acquisition of Bizotic Lifescience and Apiqo Organics received in-principle exchange approval and is slated for completion in mid-November 2026.
• CDMO segment has 3 molecules in development: Molecule 1 commercial supply delayed by 1–2 months to late Q3/early Q4FY27; validation finished for Molecules 2 & 3 with commercialisation slated for H2FY28.
• Formulation expansion underway via Anlon Medicos (tablets, capsules, and Loxoprofen topical gel filing with CDSCO/DCGI targeting approval in FY28) and new subsidiaries Anlon Biologics (peptides/biosimilars) and Anlon Medico (orthopaedic implants).
• Capital raise of up to ₹250 Cr approved by the board for biologics and subsidiary capex; funding structured with ₹65–₹70 Cr bank debt and internal accruals/equity.

Analyst Q&A

• Q. Can margins remain sustainably above 24% in Q3, Q4, and FY28?

  Price increases passed onto customers helped recover Q2 margins to 23.9%; full year FY27 should reach 25-26%, but FY28 is too early to commit though 25-27% EBITDA margin is expected if raw material prices remain stable.

• Q. What is the status of CDMO molecule commercial supplies originally targeted for Q3FY27?

  Molecule 1 commercial supply is slightly delayed by 1-2 months to late Q3 or early Q4FY27 due to client dispatch scheduling. Molecules 2 and 3 completed validation and will take 6-8 months for commercialization (H2FY28).

• Q. Why did DMF filing guidance reduce from 7 to 3-5, and what is the status of US Ketoprofen filing?

  Management clarified 3 DMFs will be filed by Dec-26 and 2-3 more in Q4FY27 (total ~6 filings in FY27). US Ketoprofen filing is currently on hold awaiting a customer US FDA inspection trigger.

• Q. Why are receivable days high (~123 days) while payable days are only 40 days, and what is the cash flow outlook?

  Shorter payable terms allow the company to negotiate discounts and counter raw material inflation; customer credit terms have been tightened to 90-100 days (from 130-140 days), enabling positive full-year operating cash flow for FY27.

• Q. What is the strategic rationale for entering medical devices/orthopaedic implants?

  The company's core pain management APIs (Ketoprofen, Dexketoprofen, Loxoprofen) target orthopaedic hospitals; medical implants allow cross-selling into the same hospital/doctor network with >25% EBITDA margin potential.

View source

Research and educational content only. Not investment advice.